ScripIn what is being hailed as the biggest ever landmark buyout involving Chinese biopharma companies, Sino Biopharmaceutical is to acquire compatriot LaNova Medicines as it endeavors to rapidly progress
Pink SheetStakeholders believe that under the US Centers for Medicare and Medicaid Services’ current approach to implementing the Medicare price negotiation program for Part B physician-administered drugs, the
Pink SheetThe US Food and Drug Administration’s approval decisions for novel agents will come from different divisions in the second half of 2025, compared to the first half, the Pink Sheet ’s US FDA Performan
ScripTariffs, What Tariffs? Despite Liberation Day’s tariff announcements coming between the end of the first quarter and the announcement of first-quarter financials, most major pharmaceutical and generic